secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K12G3
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001753926-24-001960
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.03, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Channel Therapeutics completes reincorporation from Delaware to Nevada; stockholder rights change
--------------------------------------------------------------------------------

- Chromocell Therapeutics merged into wholly-owned Nevada subsidiary Channel Therapeutics; all shares converted 1:1.
- Company name changed to Channel Therapeutics Corporation; ticker remains CHRO on NYSE American.
- Governing law shifts from DGCL to NRS; stockholder rights may differ as described in proxy statement filed Sept 26, 2024.
- Existing directors and officers remain; all prior liabilities assumed by Nevada corporation.
- Indemnification agreements updated to reflect Nevada law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001960/0001753926-24-001960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001960/g084563_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer